Polymer–Drug Conjugates Progress in Polymeric Prodrugs

Progress in Polymer Science (Impact Factor: 26.93). 04/2006; 31(4). DOI: 10.1016/j.progpolymsci.2005.09.004


Polymers are used as carriers for the delivery of drugs, proteins, targeting moieties, and imaging agents. Several polymers, poly(ethylene glycol) (PEG), N-(2-hydroxypropyl)methacrylamide (HPMA), and poly(lactide-co-glycolide) (PLGA) copolymers have been successfully utilized in clinical research. Recently, interest in polymer conjugation with biologically active components has increased remarkably as such conjugates are preferably accumulated in solid tumors and can reduce systemic toxicity. Based on the site and the mode of action, polymer conjugates possess either 'tuned' degradable or non-degradable bonds. In order to obtain such bonds, most of the strategies involve incorporation of amino acids, peptides or small chains as spacer molecules through multiple steps to include protections and deprotections. There is a need to design efficient synthetic methods to obtain polymeric conjugates with drugs and other bioactive components. Designs should aim to decrease the steric hindrance exhibited by polymers and the biocomponents. In addition, the reactivity of polymer and drug must be enhanced. This is especially true for the use of high molecular weight linear polymers and bulkier unstable drugs such as steroids and chemotherapeutic agents. Further, it is essential to elucidate the structure activity relationship (SAR) of a drug when it is conjugated with a polymer using different conjugation sites, as this can vary the efficacy and mechanism of action when compared with its free form. This review will discuss the current synthetic advances in polymer-conjugation with different bioactive components of clinical importance. In addition, the review will describe the strategies for reduction of steric hindrance and increase in reactivity of the polymers, drugs and bioactive agents and highlight the requisite structure activity relationship in polymer–drug bioconjugates. Finally, we will focus on passive and active targeting of polymeric drug delivery systems to specific site of drug action.

Full-text preview

Available from:
  • Source
    • "CLZ exerts its action by binding to the benzodiazepine site of the GABA receptors, which causes an enhancement of the electric effect of GABA binding on neurons resulting in an increased influx of chloride ions into the neurons. This results in an inhibition of synaptic transmission across the central nervous system [1] [2] [3] [4] [5] [6] [7] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many FDA approved drugs currently available in the market have limitations in crossing the blood brain barrier (BBB) owing to its complicated vasculature posed by the presence of specialized cells One of the most challenging problems, if not the most challenging, in drug development is not to develop drugs to treat diseases of the central nervous system (CNS), but to manage to distribute them to the CNS across the blood–brain barrier. The development of BBB targeting technologies is a very active field of research and development. One goal is to develop chemically modified derivatives of CNS drug (clonazepam) chemically modified nanoparticulate of drugs, capable of crossing biological barriers, in particular the BBB. Nanocarrier drug delivery involves targeting CNS drugs enclosed in a particular PVP polymer. Drug nanoparticles have been shown to improve bioavailability and enhance drug exposure for oral and parenteral dosage forms. Nanoparticles of clonazepam were prepared by many methods.
  • Source
    • "However, PNVaided chemotherapy appears to suffer from several physical barriers during the transport process [5] [6]. Unlike small drug molecules, PNVs are unable to diffuse through the cell membrane but undergo intracellular internalization via an energy-dependent endocytotic pathway [7] [8]. The entrapment of drug-loaded PNVs inside endosome/lysosome organelles is a significant limiting factor affecting the drug efficacy [9] [10] [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The present work reported the construction of a drug delivery nanovehicle via pH-sensitive assembly strategy for the improved cellular internalization and intracellular drug liberation. Through spontaneous formation of boronate linkage in the physiological condition, phenylboronic acid modified cholesterol was able to attach onto catechol-pending methoxy poly(ethylene glycol)-block-poly(L-lysine). This comb-type polymer could self-organize into micellar nanoconstruction that is able to effectively encapsulate poorly water-soluble agents. The blank micelles exhibited negligible in vitro cytotoxicity, yet the DOX-loaded micelles could effectively induce cell death at a level comparable to free DOX. Owing to the acidity-labile feature of boronate linkage, environmental pH decline from pH 7.4 to 5.0 could trigger the nanoconstruction dissociation and in turn accelerate the liberation of entrapped drugs. Importantly, the blockage of endosomal acidification in HeLa cells by NH4Cl treatment significantly decreased the nuclear uptake efficiency and cell-killing effect mediated by DOX-loaded nanoassembly, suggesting that acidity-triggered destruction of nanoconstruction is of significant importance to the enhanced drug efficacy. Moreover, confocal fluorescence microscopy and flow cytometry assay revealed the effective internalization of the nanoassemblies, and their cellular uptake efficiency exhibited a cholesterol dose-dependent profile, indicating the contribution of introduced cholesterol functionality to the transmembrane process of the nanoassembly.
    Acta Biomaterialia 05/2014; 10(8). DOI:10.1016/j.actbio.2014.05.018 · 6.03 Impact Factor
  • Source
    • "It is a micelle formed from the assembly of two different types of pluronic copolymers, L61 and F127 in 1: 8 w/w ratios [66]. Paclitaxel has been successfully loaded into PEG-b-poly(D,L-lactide) (PEG-b-PDLLA) [67] [68] [69] [70], poly(N-vinyl-pyrrolidone)-b-PDLLA (PVP-b-PDLLA) [71], PEG-b-PCL, and PEG-b-poly(d-valerolactone) (PEG-b-PVL) [72]. Genexol-PM (i.e., PEG-b- PDLLA) and NK105 (i.e., "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cytotoxic drugs are a diverse class of compounds that treat cancer primarily by killing cancerous cells that are rapidly growing and dividing along with cells that are meant for normal tissue function. A novel and suitable delivery system delivers the chemotherapeutic agents to cancerous tissues without harming healthy tissues and also retains these chemotherapeutic agents in the tumor area for a longer period of time that gives a boost to the therapy. Smaller size increases the surface area of the nanoparticles that enhances drug absorption or encapsulation and carries the drug into the blood in a shorter time period. In comparison with already existing delivery systems, nano sized delivery systems can penetrate much deeper into tumor tissue, generally taken up more efficiently by cells and reduce the toxicity of cancerous drug to healthy tissues. However, nanoparticulate systems are being researched throughout the world to increase the drug efficacy and to reduce toxicity. Thus, generally nanoparticulate systems work on passive targeting as well as on active targeting of the drug to the tumors. However, the research is still at a nascent stage and there is a need to understand the role of nano carriers in cancer treatment. This article summarizes various drug delivery technologies for chemotherapeutic agents, which are gaining more attention for better therapeutic response.
    Frontiers in Anti-Cancer Drug Discovery, VOLUME: 3 edited by Editor(s): Atta-ur-Rahman Co-Editor(s): M. Iqbal Choudhary, 05/2014: chapter Novel Strategies in the Drug Delivery Development of Anticancer Drugs: The Nanoparticulate Formulations: pages 233-261 (29); Bentham Science Publishers., ISBN: 978-1-60805-885-3
Show more